Assistant Professor of Medicine, Dana-Farber Cancer Institute
Hematology
Dr. Catherine J. Wu, MD
|
|
Give Review
Catherine works in the field of Hematology. She graduated from Stanford University School of Medicine. Stanford University School of Medicine is a top medical college. Stanford University School of Medicine is ranked 2/25 in Research/PrimaryCare. She has 1 awards "Super Doctor". Dr. Catherine J. Wu is a published physician. She published 48 publications, including: 'Mutations driving CLL and their evolution in progression and relapse.' Catherine is registered with Medicare and accepts Medicare payments.
Publications
- Mutations driving CLL and their evolution in progression and relapse.
- Haematological Malignancies: at the forefront of immunotherapeutic innovation.
- Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity.
- Molecular and genetic properties of tumors associated with local immune cytolytic activity.
- Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic Leukemia.
- Immunotherapy advances for glioblastoma.
- Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic Leukemia.
- Vaccines and Melanoma.
- HLA-Binding Properties of Tumor Neoepitopes in Humans.
- Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL.
- Reversal of in situ T cell exhaustion during effective human anti-Leukemia responses to donor lymphocyte infusion.
- Boosting Leukemia-specific T cell responses in patients following stem cell transplantation.
- Roles of nicotinic acetylcholine receptors in stem cell survival/apoptosis, proliferation and differentiation.
- Mutational heterogeneity in Cancer and the search for new Cancer-associated genes.
- Getting personal with neoantigen-based therapeutic Cancer vaccines.
- SF3B1 mutations in chronic lymphocytic Leukemia.
- CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells.
- Evolution and impact of subclonal mutations in chronic lymphocytic Leukemia.
- Nanowire-mediated delivery enables functional interrogation of primary immune cells: application to the analysis of chronic lymphocytic Leukemia.
- Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients.
- Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia.
- Enhancing graft-versus-Leukemia after transplant: the rise of anti-cancer vaccines.
- Applications of next-generation sequencing to blood and marrow transplantation.
- SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia.
- Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans.
- Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of enGraftment syndrome.
- Components of the hematopoietic compartments in tumor stroma and tumor-bearing mice.
- Data processing and analysis for protein microarrays.
- A coprecipitation-based validation methodology for interactions identified using protein microarrays.
- Graft-versus-Leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.
- Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes.
- Serologic markers of effective tumor immunity against chronic lymphocytic Leukemia include nonmutated B-cell antigens.
- Efficacious immune therapy in chronic myelogenous Leukemia (CML) recognizes antigens that are expressed on CML progenitor cells.
- Revealing tumor immunity after hematopoietic stem cell transplantation.
- Stable long-term donor enGraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease.
- A concentration-dependent analysis method for high density protein microarrays.
- Induction of tumor immunity following allogeneic stem cell transplantation.
- Evidence for ineffective erythropoiesis in severe sickle cell Disease.
- Graft-versus-Leukemia target antigens in chronic myelogenous Leukemia are expressed on myeloid progenitor cells.
- Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.
- Antibody responses to H-Y minor histocompatibility antigens correlate with Chronic graft-versus-host disease and disease remission.
- Inflammatory Myopathy Associated With Imatinib Mesylate Therapy.
- Complete response to donor lymphocyte infusion in multiple Myeloma is associated with antibody responses to highly expressed antigens.
- A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L.
- Sirolimus, tacrolimus, and low-dose methotrexate for Graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation.
- CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells.
- Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple Myeloma.
Schools
Stanford University School Of Medicine
Dana Farber Brigham and Women39s
Dana Farber Partners Cancer C
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Anemia
- Central Nervous System Lymphoma
- Chronic Myeloid Leukemia (CML)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Super Doctor
Education
-
Brigham and Women's Hospital -
Stanford University School of Medicine
Hospital
-
Massachusetts General Hospital -
Dana-Farber Cancer Institute -
Brigham and Women's Hospital
Drug Facts
| NPI NUMBER | 1710946140 | |
| NPPES Provider LastName | WU | |
| NPPES Provider FirstName | CATHERINE | |
| NPPES Provider ZIPCode | 02115 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 75.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1710946140 |
| Last Name Of The Provider | WU |
| First Name Of The Provider | CATHERINE |
| View All |
Similar Doctors
|
|
Dr. Martha Wadleigh, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marvin M. Adner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eugene H. Choi, MD |
|
|
Dr. Stefanie Sarantopoulos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James D. Griffin, MD |
|
|
Dr. Glenn Dranoff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marion F. Baxter, MD |
|
|
Dr. Lawrence N. Shulman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Corey S. Cutler, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Susana M. Campos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Kala Seetharaman, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Xiangyun He, MD |
|
|
Dr. Leonardo A. Sirulnik, MD |
|
|
Dr. Robert I. Haddad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul G. Richardson, MD |
|
|
Dr. Richard M. Stone, MD |
|
|
Dr. Matthew H. Kulke, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philippe Armand, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edwin P. Alyea III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John G. Krikorian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zachary S. Spigelman, MD
This Doctor is OpenDoctor Recommended.
|